|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Stanford University |
|---|---|
| Information provided by: | Stanford University |
| ClinicalTrials.gov Identifier: | NCT00185848 |
Purpose
The purpose of this study is to determine whether [18F]FHBG is suitable for use as an imaging probe in cancer or rheumatoid arthritis patients enrolled in gene therapy trials. In this phase 1 study we will assess the safety and biodistribution of [18F]FHBG in patients.
| Condition |
|---|
|
Central Nervous System Neoplasms Brain Cancer Glioma Arthritis, Rheumatoid |
| Study Type: | Observational |
| Study Design: | Prospective |
| Official Title: | Imaging the Biodistribution of the Positron Emission Tomography Reporter Probe, [18F]FHBG, in Humans. |
| Estimated Enrollment: | 10 |
| Study Start Date: | April 2005 |
| Estimated Primary Completion Date: | May 2010 (Final data collection date for primary outcome measure) |
The success of gene therapy depends on specific targeting of the therapeutic gene that is administered to the patient. Our goal is to develop an imaging method to non-invasively monitor the location of the therapeutic gene. Imaging should help in the design of better protocols and potentially reduce side-effects of gene therapy.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:- Clinical diagnosis of brain tumor or rheumatoid arthritis
Exclusion Criteria:- Below 18 years of age
Contacts and Locations| Contact: Shahriar Shah Yaghoubi | (650) 736-9822 | syaghoub@stanford.edu |
| United States, California | |
| Stanford University School of Medicine | Recruiting |
| Stanford, California, United States, 94305 | |
| Contact: Shahriar Shah Yaghoubi 650-736-9822 syaghoub@stanford.edu | |
| Contact: Lindee Burton (650) 721-2024 lburton@stanford.edu | |
| Principal Investigator: Sanjiv Sam Gambhir M.D., Ph.D. | |
| Sub-Investigator: Shahriar Shah Yaghoubi | |
| Sub-Investigator: Dr Lawrence Recht | |
| Sub-Investigator: Dr Andrew Quon | |
| Sub-Investigator: Michael L Goris | |
| Principal Investigator: | Sanjiv Sam Gambhir M.D., Ph.D. | Stanford University |
More Information
| Responsible Party: | Stanford University School of Medicine ( Sanjiv Sam Gambhir M.D., Ph.D., Principal Investigator ) |
| Study ID Numbers: | BRNCNS0003, 95908, BRNCNS0003, NCT00185848 |
| Study First Received: | September 12, 2005 |
| Last Updated: | June 17, 2009 |
| ClinicalTrials.gov Identifier: | NCT00185848 History of Changes |
| Health Authority: | United States: Institutional Review Board; United States: Food and Drug Administration |
|
Autoimmune Diseases Joint Diseases Arthritis, Rheumatoid Central Nervous System Diseases Central Nervous System Neoplasms Rheumatic Diseases Brain Diseases |
Brain Neoplasms Musculoskeletal Diseases Arthritis Connective Tissue Diseases Glioma Nervous System Neoplasms |
|
Autoimmune Diseases Immune System Diseases Joint Diseases Nervous System Diseases Arthritis, Rheumatoid Central Nervous System Diseases Central Nervous System Neoplasms Rheumatic Diseases |
Brain Diseases Brain Neoplasms Neoplasms Neoplasms by Site Musculoskeletal Diseases Arthritis Connective Tissue Diseases Nervous System Neoplasms |
